Zentalis Plunges More Than 70 percent in 3 Months Heres Why - Zacks Investment Research
ZNTL Stock | USD 3.10 0.03 0.96% |
About 68% of Zentalis Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Zentalis Pharmaceuticals Llc suggests that many traders are alarmed. Zentalis Pharmaceuticals' investing sentiment shows overall attitude of investors towards Zentalis Pharmaceuticals Llc.
Zentalis |
Zentalis Plunges More Than 70 percent in 3 Months Heres Why Zacks Investment Research
Read at news.google.com
Zentalis Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Zentalis Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Zentalis Pharmaceuticals Fundamental Analysis
We analyze Zentalis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zentalis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zentalis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Zentalis Pharmaceuticals is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Zentalis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zentalis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Zentalis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zentalis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Zentalis Pharmaceuticals Related Equities
PTGX | Protagonist Therapeutics | 1.51 | ||||
INZY | Inozyme Pharma | 0.67 | ||||
ANNX | Annexon | 0.44 | ||||
BPMC | Blueprint Medicines | 0.12 | ||||
RVMD | Revolution Medicines | 0.36 | ||||
SNDX | Syndax Pharmaceuticals | 1.11 | ||||
KYMR | Kymera Therapeutics | 1.49 | ||||
ERAS | Erasca | 1.52 | ||||
GLUE | Monte Rosa | 2.05 | ||||
CGEM | Cullinan Oncology | 2.13 | ||||
DAWN | Day One | 2.89 | ||||
ITOS | Iteos Therapeutics | 4.28 | ||||
OLMA | Olema Pharmaceuticals | 5.95 | ||||
SANA | Sana Biotechnology | 7.35 | ||||
DSGN | Design Therapeutics | 11.40 |
Check out Zentalis Pharmaceuticals Hype Analysis, Zentalis Pharmaceuticals Correlation and Zentalis Pharmaceuticals Performance. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.24) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.